United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The pharmaceutical giant's future should be much brighter than its recent past.

What's the Outlook for Pfizer Stock?

Brixmor Property Group

Ford Motor Company

Southwest Airlines

Snap

AT&T

Move over, roses. These stock prices will give you another reason to fall in love.

7 Stocks That Cost the Same as a Dozen Roses

Moderna

Should You Be Concerned About COVID Vaccine Efficacy Against the South African Variant?

Johnson & Johnson

It's simply not an apples-to-apples comparison.

Here's Why You Can't Compare Vaccine Results Between Johnson & Johnson, Pfizer, and Moderna

General Electric

Zoom Video

Intel

The State of Wisconsin Investment Board oversees one of the best-run pensions in America, in terms of its funding.

A Top Pension Bought More GE, Zoom, and Pfizer Stock. Here's What It Sold.

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for PANZYGA® (Immune Globulin Intravenous [Human] – ifas 10% Liquid Preparation) to treat adult patients with a rare neurological disease of the peripheral nerves called chronic inflammatory demyelinating polyneuropathy (CIDP). PANZYGA is the only intravenous immunoglobulin (IVIg) with two FDA-approved maintenance

U.S. FDA Approves PANZYGA® for the Treatment of Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

BioNTech SE

CureVac B.V

Coronavirus vaccine news supply deals and a regulatory filing are in the headlines in Friday's trading session.  US Secures More Vaccine Doses: Moderna Inc (NASDAQ: MRNA) and Pfizer Inc. (NYSE: PFE), the two companies that have received  emergency use authorization for vaccine candidates in the U.S., confirmed supply deals with the federal government.

COVID-19 Vaccine Updates: US Strikes 100M-Dose Supply Deals With Moderna, Pfizer, EU Starts Rolling Review Of CureVac Vaccine

Pfizer-BioNTech's COVID-19 vaccine was 93% effective at protecting against COVID-19, a leading Israeli healthcare provider announced Thursday. The results appear to show the shot working as hoped across a massive sample of people, raising hopes that vaccine rollouts around the world will succeed.

Pfizer's vaccine is 93% effective, Israeli healthcare giant says. It reported 0 deaths and 4 severe cases from 520,000 vaccinated people.

BioNTech SE's stock was down 0.3% and shares of Pfizer Inc. were up 0.1% in premarket trading on Friday after the companies said the U.S. now plans to purchase an additional 100 million doses of its COVID-19 vaccine for $1.95 billion. This brings the total number of vaccine doses supplied in the U.S. by BioNTech and Pfizer to 300 million.

U.S. orders another 100 million doses of the BioNTech/Pfizer COVID-19 vaccine

The Pfizer vaccine could protect against the new variants of the coronavirus, according to data from a new study cited by the Guardian. The vaccine led to promising results when tested against two variants widely feared by health experts, one first found in the UK, and another first found in South Africa.

The Pfizer vaccine could be effective against the 2 most dangerous COVID-19 variants, according to new data

How Long Until We Reach Herd Immunity? Expert Timelines Vary

Pfizer offers an attractive dividend yield and a conservative P/E ratio. The safety and quantum of Pfizer's dividend likely outweighs the potential for relatively slow dividend growth.

Pfizer: Buy It For A Safe 4% Plus Dividend Yield

A huge pivot could reopen doors to growth that seemed closed.

3 Reasons Pfizer's Failures Could Lead to a Big Acquisition

Emergent BioSolutions

Regeneron Pharmaceuticals

These stocks would be buys even without the pandemic.

3 Absurdly Cheap Coronavirus Stocks to Buy Now

The big drugmaker hoped for better news from a safety study of its blockbuster drug.

How Bad News for Xeljanz Could Affect Pfizer's Fortunes

Pfizer stock fell after the earnings report fell short of estimates. Revenue has declined in the past several years but is now rising. Additionally, Pfizer has a low P/E ratio. Pfizer's 50-week moving average is just below the trend line at $34.01, giving the stock two layers of support in the same area.

Look For A Bounce In Pfizer After 2-Month Pullback

JPMorgan Chase & Co

Wells Fargo

Here's why Wall Street has Feb. 15 circled on its calendar.

The Warren Buffett News You Won't Want to Miss Is 5 Days Away

Hint: Better than the company's recent Q4 results might make you think.

What Are Pfizer's Prospects in 2021 and Beyond?

Pfizer's COVID-19 vaccine provides protection against the highly contagious variant of the virus that emerged in South Africa, a new study shows. People who received the Pfizer shots had higher levels of antibodies capable of neutralizing the strain than those found in patients who contracted the bug, New York University researchers found.

Pfizer COVID-19 vaccine should ward off South Africa strain, study shows

Company is just off the back of announcing its 2020 numbers.

Pfizer: Fundamentals Point To Higher Prices

Merck

Investors are enamored with high profile stocks and ignoring ones that are solid investments. Here are three biotech stocks to consider.

3 Under-the-Radar Biotech Stocks to Buy After Dull Earnings Reactions

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announced a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc. for BAVENCIO® (avelumab), the first and only immunotherapy approved as a first-line maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma. BA

4D pharma Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate MRx0518 in Combination with BAVENCIO® for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma

4D pharma PLC (LON:DDDD) has signed a clinical trial collaboration and supply agreement with Merck KGaA, and Pfizer Inc. As part of the tie-up, 4D pharma will start a clinical trial this year with BAVENCIO, a drug for advanced or metastatic urothelial carcinoma developed by Merck and Pfizer, in combination with UK group's MRx0518. "With this second clinical trial collaboration for MRx0518 with a leading immune checkpoint inhibitor, 4D is able to evaluate MRx0518 in a new combination and earlier treatment setting,” said 4D chief executive Duncan Peyton.

4D pharma PLC inks clinical trial collaboration and supply agreement with Merck KGaA, and Pfizer Inc

Updates on the COVID-19 vaccine and plans for a more focused structure dominated the release.

1 Green Flag and 1 Red Flag From Pfizer's Earnings

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Patent and Trademark Office (USPTO) recently issued a U.S. Patent Term Extension (PTE) certificate for IBRANCE® (palbociclib). The certificate extends the term of U.S. Patent No. RE47,739 (‘739) by more than four years until March 5, 2027. The PTE certificate was granted under the patent restoration provisions of the Drug Price Competition and Patent Term Restoration Act of 1984. This PTE will be listed in Approved

News for Pfizer Stock (PFE)